The Exchange had sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE had asked Lincoln Pharmaceuticals to explain why segment-wise details were not included in their financial results for the quarter and year ended March 2025. The company replied that it operates in only a single business segment — 'Pharmaceutical Business' — and therefore segment reporting under Accounting Standard AS-17 / Ind AS 108 does not apply to it. The company referenced Note 5 of its standalone financial statements, which also states this. The clarification was signed by the Company Secretary & Compliance Officer on 24th June 2025.
This is a routine compliance clarification, not a penalty or adverse action. The company has explained that segment reporting is not applicable due to its single-segment operations, so no material impact on shareholders or the stock is expected.